Skip to content
Back to meeting Original
Aya Mohamed | MSc, MD 🎗· @Dr_Oncologista · X·· 2 days agoScore45

olaparib

Body

TOMAS2: PARP1 H-score as a Potential Biomarker for Trabectedin + Olaparib in Sarcoma

@OncoAlert #ESMO26 #ESMOAmbassadors #ESMOcommunity @myESMO

6 views · 0 likes · 0 reposts · 0 replies

Conference abstracts
LBA37matched by Proffered paper: Gynaecological cancers

Durvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud

https://esmocongress.esmo.org

Source: Aya Mohamed | MSc, MD 🎗 · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.